JP2016502858A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016502858A5 JP2016502858A5 JP2015549818A JP2015549818A JP2016502858A5 JP 2016502858 A5 JP2016502858 A5 JP 2016502858A5 JP 2015549818 A JP2015549818 A JP 2015549818A JP 2015549818 A JP2015549818 A JP 2015549818A JP 2016502858 A5 JP2016502858 A5 JP 2016502858A5
- Authority
- JP
- Japan
- Prior art keywords
- antisense oligonucleotide
- base
- oligonucleotide
- antisense
- target region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108091034117 Oligonucleotide Proteins 0.000 claims description 84
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 69
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 69
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims description 18
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims description 18
- 230000000692 anti-sense effect Effects 0.000 claims description 9
- 229940113082 thymine Drugs 0.000 claims description 9
- 229940035893 uracil Drugs 0.000 claims description 9
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 7
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims description 6
- 102220492049 Phospholipid scramblase 1_H53A_mutation Human genes 0.000 claims description 6
- 238000000137 annealing Methods 0.000 claims description 6
- 230000000295 complement effect Effects 0.000 claims description 6
- 239000002773 nucleotide Substances 0.000 claims description 6
- 125000003729 nucleotide group Chemical group 0.000 claims description 5
- -1 5-substituted pyrimidine Chemical class 0.000 claims description 4
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 4
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 4
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical group CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims description 2
- MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 claims description 2
- 239000004475 Arginine Substances 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- 230000004700 cellular uptake Effects 0.000 claims description 2
- 229940104302 cytosine Drugs 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 125000003827 glycol group Chemical group 0.000 claims description 2
- 201000006938 muscular dystrophy Diseases 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims 6
- 101001053946 Homo sapiens Dystrophin Proteins 0.000 claims 5
- 108020004999 messenger RNA Proteins 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 3
- 108010069091 Dystrophin Proteins 0.000 description 2
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 description 1
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 101710203526 Integrase Proteins 0.000 description 1
- 108091093037 Peptide nucleic acid Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- BOKOVLFWCAFYHP-UHFFFAOYSA-N dihydroxy-methoxy-sulfanylidene-$l^{5}-phosphane Chemical compound COP(O)(O)=S BOKOVLFWCAFYHP-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical group CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261739968P | 2012-12-20 | 2012-12-20 | |
| US61/739,968 | 2012-12-20 | ||
| PCT/US2013/077216 WO2014100714A1 (en) | 2012-12-20 | 2013-12-20 | Improved exon skipping compositions for treating muscular dystrophy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018081272A Division JP2018110601A (ja) | 2012-12-20 | 2018-04-20 | 筋ジストロフィを処置するための改善されたエキソンスキッピング組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016502858A JP2016502858A (ja) | 2016-02-01 |
| JP2016502858A5 true JP2016502858A5 (OSRAM) | 2017-02-02 |
Family
ID=49950080
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015549818A Withdrawn JP2016502858A (ja) | 2012-12-20 | 2013-12-20 | 筋ジストロフィを処置するための改善されたエキソンスキッピング組成物 |
| JP2018081272A Pending JP2018110601A (ja) | 2012-12-20 | 2018-04-20 | 筋ジストロフィを処置するための改善されたエキソンスキッピング組成物 |
| JP2019003308A Pending JP2019050834A (ja) | 2012-12-20 | 2019-01-11 | 筋ジストロフィを処置するための改善されたエキソンスキッピング組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018081272A Pending JP2018110601A (ja) | 2012-12-20 | 2018-04-20 | 筋ジストロフィを処置するための改善されたエキソンスキッピング組成物 |
| JP2019003308A Pending JP2019050834A (ja) | 2012-12-20 | 2019-01-11 | 筋ジストロフィを処置するための改善されたエキソンスキッピング組成物 |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US20150361428A1 (OSRAM) |
| EP (2) | EP2935584A1 (OSRAM) |
| JP (3) | JP2016502858A (OSRAM) |
| KR (2) | KR20200143739A (OSRAM) |
| CN (2) | CN106414739A (OSRAM) |
| AU (3) | AU2013364158A1 (OSRAM) |
| BR (1) | BR112015014987A2 (OSRAM) |
| CA (1) | CA2894899A1 (OSRAM) |
| EA (1) | EA201591178A1 (OSRAM) |
| HK (1) | HK1216902A1 (OSRAM) |
| IL (1) | IL239491A0 (OSRAM) |
| MX (2) | MX2015008035A (OSRAM) |
| WO (1) | WO2014100714A1 (OSRAM) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE498685T1 (de) | 2004-06-28 | 2011-03-15 | Univ Western Australia | Antisense-oligonukleotide zur induktion von exon- skipping sowie verfahren zur verwendung davon |
| AU2006213686A1 (en) | 2005-02-09 | 2006-08-17 | Avi Bio Pharma, Inc. | Antisense composition and method for treating muscle atrophy |
| TR201902952T4 (tr) | 2008-10-24 | 2019-03-21 | Sarepta Therapeutics Inc | Dmd için ekson atlama bileşimleri. |
| CA2780563C (en) | 2009-11-12 | 2025-05-06 | Univ Western Australia | Antisense Molecules and Methods for Treating Pathologies |
| TWI541024B (zh) | 2010-09-01 | 2016-07-11 | 日本新藥股份有限公司 | 反義核酸 |
| US20130085139A1 (en) | 2011-10-04 | 2013-04-04 | Royal Holloway And Bedford New College | Oligomers |
| NZ775701A (en) | 2013-03-14 | 2022-08-26 | Sarepta Therapeutics Inc | Exon skipping compositions for treating muscular dystrophy |
| HUE042218T2 (hu) * | 2013-03-14 | 2019-06-28 | Sarepta Therapeutics Inc | Exonátugrást elõsegítõ készítmények izomdisztrófia kezelésére |
| NZ732507A (en) | 2013-03-15 | 2018-08-31 | Sarepta Therapeutics Inc | Improved compositions for treating muscular dystrophy |
| MA41795A (fr) | 2015-03-18 | 2018-01-23 | Sarepta Therapeutics Inc | Exclusion d'un exon induite par des composés antisens dans la myostatine |
| HUE052604T2 (hu) * | 2015-04-08 | 2021-05-28 | Univ Chicago | Készítmények és eljárások 2C típusú végtag-öv izomdisztrófia javítására exon-átugrás alkalmazásával |
| MA45819A (fr) | 2015-10-09 | 2018-08-15 | Sarepta Therapeutics Inc | Compositions et méthodes pour traiter la dystrophie musculaire de duchenne et troubles associés |
| FR3044926B1 (fr) | 2015-12-09 | 2020-01-31 | Genethon | Outils de therapie genique efficaces pour le saut de l'exon 53 de la dystrophine |
| JOP20200228A1 (ar) | 2015-12-21 | 2017-06-16 | Novartis Ag | تركيبات وطرق لخفض تعبير البروتين tau |
| WO2017136435A1 (en) | 2016-02-01 | 2017-08-10 | The Usa, As Represented By The Secretary, Department Of Health And Human Services Office Of Technology Transfer National Institute Of Health | Compounds for modulating fc-epsilon-ri-beta expression and uses thereof |
| MA45328A (fr) | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Compositions acide nucléique-polypeptide et utilisations de celles-ci |
| KR20190024977A (ko) | 2016-06-30 | 2019-03-08 | 사렙타 쎄러퓨틱스 인코퍼레이티드 | 근육 이상증에 대한 엑손 스킵핑 올리고머 |
| WO2018009547A1 (en) | 2016-07-05 | 2018-01-11 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Diagnosing col6-related disorders and methods for treating same |
| US10898566B2 (en) | 2016-09-19 | 2021-01-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Zika virus vaccines |
| KR20240006057A (ko) | 2016-12-19 | 2024-01-12 | 사렙타 쎄러퓨틱스 인코퍼레이티드 | 근육 이상증에 대한 엑손 스킵핑 올리고머 결합체 |
| WO2018118627A1 (en) | 2016-12-19 | 2018-06-28 | Sarepta Therapeutics, Inc. | Exon skipping oligomer conjugates for muscular dystrophy |
| MD3554553T2 (ro) | 2016-12-19 | 2022-10-31 | Sarepta Therapeutics Inc | Conjugați de oligomeri de omitere a exonului, pentru distrofie musculară |
| WO2018129384A1 (en) | 2017-01-06 | 2018-07-12 | Avidity Biosciences Llc | Nucleic acid-polypeptide compositions and methods of inducing exon skipping |
| WO2018152526A1 (en) | 2017-02-20 | 2018-08-23 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Zika virus vaccines |
| GB201711809D0 (en) * | 2017-07-21 | 2017-09-06 | Governors Of The Univ Of Alberta | Antisense oligonucleotide |
| EA201991450A1 (ru) * | 2017-09-22 | 2019-12-30 | Сарепта Терапьютикс, Инк. | Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии |
| WO2019209764A2 (en) * | 2018-04-26 | 2019-10-31 | Sarepta Therapeutics, Inc. | Exon skipping oligomers and oligomer conjugates for muscular dystrophy |
| US10765760B2 (en) | 2018-05-29 | 2020-09-08 | Sarepta Therapeutics, Inc. | Exon skipping oligomer conjugates for muscular dystrophy |
| IL318474A (en) * | 2018-12-13 | 2025-03-01 | Sarepta Therapeutics Inc | Axon-skipping oligomer complexes for muscular dystrophy |
| CN118516348B (zh) * | 2024-07-23 | 2025-01-17 | 深川生物科技(山东)股份公司 | 单链核酸或双链核酸及在制备治疗杜氏肌营养不良的药物中的应用 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH445129A (fr) | 1964-04-29 | 1967-10-15 | Nestle Sa | Procédé pour la préparation de composés d'inclusion à poids moléculaire élevé |
| US3459731A (en) | 1966-12-16 | 1969-08-05 | Corn Products Co | Cyclodextrin polyethers and their production |
| US3426011A (en) | 1967-02-13 | 1969-02-04 | Corn Products Co | Cyclodextrins with anionic properties |
| US3453257A (en) | 1967-02-13 | 1969-07-01 | Corn Products Co | Cyclodextrin with cationic properties |
| US3453259A (en) | 1967-03-22 | 1969-07-01 | Corn Products Co | Cyclodextrin polyol ethers and their oxidation products |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| US5166315A (en) | 1989-12-20 | 1992-11-24 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
| US5506337A (en) | 1985-03-15 | 1996-04-09 | Antivirals Inc. | Morpholino-subunit combinatorial library and method |
| US5185444A (en) | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
| US5521063A (en) | 1985-03-15 | 1996-05-28 | Antivirals Inc. | Polynucleotide reagent containing chiral subunits and methods of use |
| US5217866A (en) | 1985-03-15 | 1993-06-08 | Anti-Gene Development Group | Polynucleotide assay reagent and method |
| DE3687030T2 (de) | 1985-03-15 | 1993-03-11 | Eugene Stirchak | Stereoregulare polynukleotiden bindende polymere. |
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| US4737323A (en) | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5149797A (en) | 1990-02-15 | 1992-09-22 | The Worcester Foundation For Experimental Biology | Method of site-specific alteration of rna and production of encoded polypeptides |
| EP0786522A2 (en) | 1992-07-17 | 1997-07-30 | Ribozyme Pharmaceuticals, Inc. | Enzymatic RNA molecules for treatment of stenotic conditions |
| PT698092E (pt) | 1993-05-11 | 2007-10-29 | Univ North Carolina | Oligonucleótidos complementares de uma cadeia codificadora que combatem splicing aberrante e métodos para a sua utilização |
| US5820873A (en) | 1994-09-30 | 1998-10-13 | The University Of British Columbia | Polyethylene glycol modified ceramide lipids and liposome uses thereof |
| US5753613A (en) | 1994-09-30 | 1998-05-19 | Inex Pharmaceuticals Corporation | Compositions for the introduction of polyanionic materials into cells |
| US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
| IL115849A0 (en) | 1994-11-03 | 1996-01-31 | Merz & Co Gmbh & Co | Tangential filtration preparation of liposomal drugs and liposome product thereof |
| WO1999042091A2 (en) | 1998-02-19 | 1999-08-26 | Massachusetts Institute Of Technology | Use of polycations as endosomolytic agents |
| US6683173B2 (en) | 1998-04-03 | 2004-01-27 | Epoch Biosciences, Inc. | Tm leveling methods |
| US6210892B1 (en) | 1998-10-07 | 2001-04-03 | Isis Pharmaceuticals, Inc. | Alteration of cellular behavior by antisense modulation of mRNA processing |
| EP1242052A4 (en) | 1999-12-29 | 2003-07-02 | A James Mixson | HISTIDIN COPOLYMER AND METHODS OF USE THEREOF |
| US7070807B2 (en) | 1999-12-29 | 2006-07-04 | Mixson A James | Branched histidine copolymers and methods for using same |
| EP1390490B1 (en) | 2001-05-24 | 2009-04-15 | Genzyme Corporation | Muscle-specific expression vectors |
| ATE498685T1 (de) | 2004-06-28 | 2011-03-15 | Univ Western Australia | Antisense-oligonukleotide zur induktion von exon- skipping sowie verfahren zur verwendung davon |
| KR101789603B1 (ko) | 2005-11-10 | 2017-11-21 | 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 | Ｔｎｆ 수퍼패밀리 수용체에 대한 스플라이스 스위칭올리고머 및 염증성 질환 치료용 약제학적 조성물 |
| ES2645410T3 (es) | 2006-05-10 | 2017-12-05 | Sarepta Therapeutics, Inc. | Análogos de oligonucleótidos que tienen enlaces intersubunitarios catiónicos |
| US20100016215A1 (en) | 2007-06-29 | 2010-01-21 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
| US8076476B2 (en) | 2007-11-15 | 2011-12-13 | Avi Biopharma, Inc. | Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits |
| US8299206B2 (en) | 2007-11-15 | 2012-10-30 | Avi Biopharma, Inc. | Method of synthesis of morpholino oligomers |
| WO2009127230A1 (en) | 2008-04-16 | 2009-10-22 | Curevac Gmbh | MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION |
| US8084601B2 (en) * | 2008-09-11 | 2011-12-27 | Royal Holloway And Bedford New College Royal Holloway, University Of London | Oligomers |
| TR201902952T4 (tr) * | 2008-10-24 | 2019-03-21 | Sarepta Therapeutics Inc | Dmd için ekson atlama bileşimleri. |
| CA2780563C (en) * | 2009-11-12 | 2025-05-06 | Univ Western Australia | Antisense Molecules and Methods for Treating Pathologies |
| EP2576574A2 (en) | 2010-05-28 | 2013-04-10 | Sarepta Therapeutics, Inc. | Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups |
| TWI541024B (zh) * | 2010-09-01 | 2016-07-11 | 日本新藥股份有限公司 | 反義核酸 |
| KR102183273B1 (ko) | 2011-05-05 | 2020-11-27 | 사렙타 쎄러퓨틱스, 인코퍼레이티드 | 펩타이드 올리고뉴클레오타이드 접합체 |
-
2013
- 2013-12-20 WO PCT/US2013/077216 patent/WO2014100714A1/en not_active Ceased
- 2013-12-20 EP EP13819166.3A patent/EP2935584A1/en not_active Withdrawn
- 2013-12-20 CA CA2894899A patent/CA2894899A1/en not_active Abandoned
- 2013-12-20 CN CN201380073536.XA patent/CN106414739A/zh active Pending
- 2013-12-20 MX MX2015008035A patent/MX2015008035A/es unknown
- 2013-12-20 KR KR1020207033842A patent/KR20200143739A/ko not_active Ceased
- 2013-12-20 HK HK16104638.2A patent/HK1216902A1/zh unknown
- 2013-12-20 AU AU2013364158A patent/AU2013364158A1/en not_active Abandoned
- 2013-12-20 BR BR112015014987A patent/BR112015014987A2/pt not_active Application Discontinuation
- 2013-12-20 EP EP21152285.9A patent/EP3885439A1/en not_active Withdrawn
- 2013-12-20 EA EA201591178A patent/EA201591178A1/ru unknown
- 2013-12-20 JP JP2015549818A patent/JP2016502858A/ja not_active Withdrawn
- 2013-12-20 KR KR1020157019523A patent/KR20150099804A/ko not_active Ceased
- 2013-12-20 CN CN202010276936.2A patent/CN111440796A/zh active Pending
-
2015
- 2015-06-18 US US14/743,856 patent/US20150361428A1/en not_active Abandoned
- 2015-06-18 IL IL239491A patent/IL239491A0/en unknown
- 2015-06-19 MX MX2019008164A patent/MX2019008164A/es unknown
-
2017
- 2017-01-31 US US15/420,823 patent/US20170369875A1/en not_active Abandoned
-
2018
- 2018-04-20 JP JP2018081272A patent/JP2018110601A/ja active Pending
-
2019
- 2019-01-11 JP JP2019003308A patent/JP2019050834A/ja active Pending
- 2019-10-21 AU AU2019253778A patent/AU2019253778A1/en not_active Abandoned
- 2019-12-04 US US16/703,110 patent/US20200339985A1/en not_active Abandoned
-
2021
- 2021-10-11 US US17/498,115 patent/US20220259592A1/en not_active Abandoned
-
2022
- 2022-03-09 AU AU2022201628A patent/AU2022201628A1/en not_active Abandoned
- 2022-05-11 US US17/741,758 patent/US20230104708A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016502858A5 (OSRAM) | ||
| JP2015504650A5 (OSRAM) | ||
| JP2013510561A5 (OSRAM) | ||
| JP6977998B2 (ja) | アンチセンス核酸 | |
| RU2016139108A (ru) | Антисмысловые нуклеиновые кислоты | |
| JP2018529732A5 (OSRAM) | ||
| JP2018507711A5 (OSRAM) | ||
| JP2015523854A5 (OSRAM) | ||
| JP2018110601A5 (OSRAM) | ||
| JP2016513976A5 (OSRAM) | ||
| JP2016522674A5 (OSRAM) | ||
| JP2015518710A5 (OSRAM) | ||
| HRP20160225T1 (hr) | Antisens olinukleotidi za induciranje zaobilaženja egzona i postupci njihove upotrebe | |
| JP2016116520A5 (OSRAM) | ||
| IL300119A (en) | Oligonucleotides for inducing paternal ube3a expression | |
| JP2010539950A5 (OSRAM) | ||
| JP2010515707A5 (OSRAM) | ||
| JP2017505623A5 (OSRAM) | ||
| JP2014054250A5 (OSRAM) | ||
| JP2016521556A5 (OSRAM) | ||
| JP2018520685A5 (OSRAM) | ||
| JP2015518713A5 (OSRAM) | ||
| JP2015518712A5 (OSRAM) | ||
| JP2015523853A5 (OSRAM) | ||
| JP2019533472A5 (OSRAM) |